• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Plasma thromboplastin antecedent (PTA) deficiency; clinical, coagulation, therapeutic and hereditary aspects of a new hemophilia-like disease.

作者信息

ROSENTHAL R L, DRESKIN O H, ROSENTHAL N

出版信息

Blood. 1955 Feb;10(2):120-31.

PMID:13230164
Abstract
摘要

相似文献

1
Plasma thromboplastin antecedent (PTA) deficiency; clinical, coagulation, therapeutic and hereditary aspects of a new hemophilia-like disease.血浆凝血活酶前体（PTA）缺乏症；一种新型血友病样疾病的临床、凝血、治疗及遗传方面
Blood. 1955 Feb;10(2):120-31.
2
[HEMORRHAGIC DIATHESIS CAUSED BY A DEFICIENCY OF PLASMA-THROMBOPLASTIN-ANTECEDENT (PTA)].[血浆凝血活酶前体（PTA）缺乏引起的出血素质]
Ned Tijdschr Geneeskd. 1964 Jan 18;108:118-27.
3
[Individualization of a third plasmatic factor of thromboplastin (plasma thromboplastin antecedent) the deficiency of which causes a hemorrhagic disease similar to hemophilia].
Prog Med (Napoli). 1953 Jun 15;9(11):333-6.
4
PROLONGED POSTOPERATIVE BLEEDING IN A PATIENT WITH FACTOR XI (PTA) DEFICIENCY.一名患有因子XI（PTA）缺乏症患者的术后长期出血
Ann Surg. 1965 Jul;162(1):37-42. doi: 10.1097/00000658-196507000-00006.
5
[BLOOD COAGULATION RESEARCH IN 3 CASES OF PTA HEMOPHILIA (CAUSED BY FACTOR XI DEFICIENCY) OF A MAJOR TYPE].3例重型PTA血友病（因子Ⅺ缺乏所致）的血液凝固研究
Haematologica. 1963;48:679-96.
6
Studies on plasma thromboplastin antecedent (factor XI), PTA deficiency and inhibition of PTA by plasma: pharmacologic inhibitors and specific antiserum.血浆凝血活酶前体（因子XI）、PTA缺乏及血浆对PTA的抑制作用的研究：药理抑制剂和特异性抗血清
J Lab Clin Med. 1972 Jan;79(1):113-27.
7
The correction of a hemorrhagic diathesis in preparation for surgery; the correction of plasma thromboplastin antecedent deficiency.为手术做准备纠正出血素质；纠正血浆促凝血酶原激酶前体缺乏。
AMA Arch Intern Med. 1957 Sep;100(3):474-7. doi: 10.1001/archinte.1957.00260090130018.
8
Plasma thromboplastin antecedent (PTA) deficiency.
AMA Arch Intern Med. 1957 Aug;100(2):232-40. doi: 10.1001/archinte.1957.00260080058012.
9
HAEMORRHAGIC DIATHESIS AS THE RESULT OF SEVERE DEFICIENCY OF PLASMA THROMBOPLASTIN ANTECEDENT (PTA, FACTOR XI).血浆凝血活酶前体（PTA，因子XI）严重缺乏导致的出血素质
Thromb Diath Haemorrh. 1964 Apr 15;11:166-86.
10
Bleeding from deficiency of plasma thromboplastin antecedent (PTA) coagulation factor; report of a case.血浆凝血活酶前体（PTA）凝血因子缺乏所致出血；病例报告。
Oral Surg Oral Med Oral Pathol. 1957 Mar;10(3):225-9. doi: 10.1016/0030-4220(57)90085-3.

引用本文的文献

1
Design, synthesis, and biological evaluation of substituted oxopyridine derivatives as selective FXIa inhibitors.作为选择性因子XIa抑制剂的取代氧代吡啶衍生物的设计、合成及生物学评价
RSC Med Chem. 2025 May 28. doi: 10.1039/d4md01013b.
2
Targeting factor XI and factor XIa to prevent thrombosis.靶向因子 XI 和因子 XIa 以预防血栓形成。
Blood. 2024 Apr 11;143(15):1465-1475. doi: 10.1182/blood.2023020722.
3
Factor XIa Inhibitors as a Novel Anticoagulation Target: Recent Clinical Research Advances.作为新型抗凝靶点的凝血因子XIa抑制剂：近期临床研究进展
Pharmaceuticals (Basel). 2023 Jun 11;16(6):866. doi: 10.3390/ph16060866.
4
Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment.肾功能正常和中重度肾功能损害受试者中单剂量米伏先的药代动力学。
Clin Pharmacokinet. 2022 Oct;61(10):1405-1416. doi: 10.1007/s40262-022-01150-1. Epub 2022 Jul 30.
5
A Common Missense Variant Causing Factor XI Deficiency and Increased Bleeding Tendency in Maine Coon Cats.导致缅因猫因子 XI 缺乏和出血倾向增加的常见错义变异。
Genes (Basel). 2022 Apr 28;13(5):792. doi: 10.3390/genes13050792.
6
Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants.在健康的日本参与者中评估 milvexian 的安全性、药代动力学和药效学。
Sci Rep. 2022 Mar 25;12(1):5165. doi: 10.1038/s41598-022-08768-y.
7
Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants.轻度或中度肝损伤参与者与健康参与者单次剂量米尔维生的药代动力学比较。
Clin Pharmacokinet. 2022 Jun;61(6):857-867. doi: 10.1007/s40262-022-01110-9. Epub 2022 Mar 9.
8
First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor.首例人体研究milvexian，一种口服、直接、小分子因子 XIa 抑制剂。
Clin Transl Sci. 2022 Feb;15(2):330-342. doi: 10.1111/cts.13148. Epub 2021 Sep 24.
9
Successful perioperative management in a patient with factor XI deficiency.XI因子缺乏患者的围手术期成功管理。
BMJ Case Rep. 2018 Feb 21;2018:bcr-2017-222434. doi: 10.1136/bcr-2017-222434.
10
Why factor XI deficiency is a clinical concern.为什么因子 XI 缺乏症是一个临床关注点。
Expert Rev Hematol. 2016 Jul;9(7):629-37. doi: 10.1080/17474086.2016.1191944. Epub 2016 Jun 24.